Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer

Lead Sponsor:

National Cancer Institute (NCI)

Conditions:

Fallopian Tube Cancer

Female Reproductive Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

This trial is studying the side effects and best dose of ixabepilone when given together with pegylated liposomal doxorubicin hydrochloride and to see how well they work in treating women with advance...

Detailed Description

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose and recommended phase II dose of ixabepilone when combined with pegylated doxorubicin hydrochloride (HCl) liposome (pegylated liposomal ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Histologically or cytologically confirmed diagnosis of 1 of the following: advanced ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer (phase I and II) or metastatic breast cancer (phase I only).
  • Platinum- and taxane-resistant disease, defined as a disease-free interval of \< 6 months after completion of platinum- and taxane-based chemotherapy. Disease progression during the regimen (phase II) or previously treated with \>= 2 prior regimens for metastatic breast cancer, including 1 taxane-based regimen in the adjuvant or metastatic setting (phase I).
  • Meets 1 of the following criteria: Previously treated with a standard course of taxane- and platinum-based chemotherapy for ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer, that is platinum-refractory or -sensitive disease (phase I );
  • Measurable or evaluable disease, meeting 1 of the following criteria: unidimensionally measurable lesion, known disease and CA 125 \> 50 U/mL on 2 occasions \>= 1 week apart or known disease and CA 27-29, CA 15-3, or CA 125 \> 50 U/mL on 2 occasions \>= 1 week apart (for breast cancer patients)
  • ECOG 0-2 or Karnofsky 60-100%
  • At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered.
  • At least 1 week since prior chemotherapy if given on a daily or weekly schedule and recovered.
  • At least 3 weeks since prior radiotherapy and recovered.
  • Recovered for more than 4 weeks from all adverse events related to prior agents.
  • Normal organ function including:
  • Normal bilirubin
  • WBC \>= 3,000/mm3
  • Absolute neutrophil count \>= 1,500/mm3
  • Platelet count \>= 100,000/mm3
  • AST and ALT =\< 2.5 times upper limit of normal (ULN)
  • Creatinine =\< 1.5 times ULN or Creatinine clearance ≥ 60 mL/min
  • Exclusion criteria:
  • No other concurrent investigational agents.
  • No concurrent combination antiretroviral therapy for HIV-positive patients.
  • No other concurrent anticancer therapy.
  • Has received a previous chemotherapy regimen for this cancer that included drugs such as docetaxel or paclitaxel.
  • Life expectancy of more than 3 months
  • No symptomatic congestive heart failure
  • No unstable angina pectoris
  • No cardiac arrhythmia
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No history of allergic reaction attributed to compounds of similar chemical or biological composition to Cremophor® or study drugs
  • No neuropathy \>= grade 2
  • No ongoing or active infection
  • No psychiatric illness or social situation that would preclude study compliance.
  • No other uncontrolled illness.
  • No active brain metastases, including any of the following: evidence of cerebral edema by CT scan or MRI, evidence of disease progression on prior imaging studies, requirement for steroids or clinical symptoms of brain metastasis.

Exclusion

    Key Trial Info

    Start Date :

    January 1 2006

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    May 1 2014

    Estimated Enrollment :

    45 Patients enrolled

    Trial Details

    Trial ID

    NCT00182767

    Start Date

    January 1 2006

    End Date

    May 1 2014

    Last Update

    March 10 2016

    Active Locations (5)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (5 locations)

    1

    University of Connecticut

    Farmington, Connecticut, United States, 06030

    2

    Women's Cancer Care Associates LLC

    Albany, New York, United States, 12208

    3

    Weill Medical College of Cornell University

    New York, New York, United States, 10065

    4

    Albert Einstein College of Medicine

    The Bronx, New York, United States, 10461